🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalIreland HSE coverage for Wegovy — 12 month update Page 3

Ireland HSE coverage for Wegovy — 12 month update

sarah.morrison Wed, Jun 4, 2025 at 1:21 PM 25 replies 1,558 viewsPage 3 of 5
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Jun 5, 2025 at 2:30 AM#11
MASHdoc_SA said:
The mechanism that matters here is not stomach emptying, it is central.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Last edited: Jun 5, 2025 at 3:30 AM
36 11Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 33 others
Reply Quote Save Share Report
ben_calgary
Member
245
1,123
Oct 2024
Calgary, CA
Jun 5, 2025 at 10:45 AM#12
KevinCompounds said:
All true, with one condition: that curve is for people who reached the dose on schedule.

This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.

Last edited: Jun 5, 2025 at 4:45 PM
35 10CanadaChris, ZaraB_AL, JakeSmashed95 and 32 others
Reply Quote Save Share Report
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Jun 5, 2025 at 7:00 PM#13
MASHdoc_SA said:
The mechanism that matters here is not stomach emptying, it is central.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

34 9james_edin, FranDenver, Dr.BariatricHTX and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jun 6, 2025 at 3:15 AM#14
sarah.morrison said:
The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

Insurance update relevant to cost and coverage: I just got my prior auth approved through Blue Cross after 4 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (NAFLD + metabolic syndrome), and referencing the SELECT trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

33 8DebRD_ATL, KristenIndy, MarkLI_maint and 30 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 6, 2025 at 11:30 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.

32 7PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 29 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register